Fecal incontinence after moderately hypofractionated volumetric modulated arc therapy for prostate cancer: incidence and impact on quality of life.

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-10-01 Epub Date: 2025-04-22 DOI:10.1007/s12094-025-03926-w

Joan Lozano, Nicolas Feltes, Montserrat Colomer, Maria Lizondo, Mamen Carmona, Clara Romero, Yolanda Ribas, Saturio Paredes, Manuel Galdeano, Josep Maria Solé

{"title":"Fecal incontinence after moderately hypofractionated volumetric modulated arc therapy for prostate cancer: incidence and impact on quality of life.","authors":"Joan Lozano, Nicolas Feltes, Montserrat Colomer, Maria Lizondo, Mamen Carmona, Clara Romero, Yolanda Ribas, Saturio Paredes, Manuel Galdeano, Josep Maria Solé","doi":"10.1007/s12094-025-03926-w","DOIUrl":null,"url":null,"abstract":"Purpose: Fecal incontinence (FI) is a late toxicity consequence in prostate cancer patients treated with current radiotherapy schedules that remains poorly described and understood. The main objective of this work is to describe the incidence of appearance of FI in these patients, and to analyze whether this late radiotoxicity event affects the quality of life of survivors.Methods: Prospective follow-up study was performed on a cohort of 91 patients with non-metastatic prostate cancer undergoing moderately hypofractionated volumetric modulated arc therapy (VMAT at 2.5-3 Gy/session) with image-guided radiotherapy (IGRT) in a real-world clinical practice scenario. The incidence of FI (using the Vaizey score) and FI-free survival time after completion of radiotherapy were presented. We additionally assessed the scores on the FI Quality of Life (FIQL) scale in both patients with and without FI.Results: Within 2 years after radiotherapy, 10 of 91 patients (11%) showed some degree of FI with an average onset at 13.59 months. Patients with some degree of FI had worse FIQL scores than those without FI (p < 0.001).Conclusion: Patients with localized prostate cancer treated with moderately hypofractionated VMAT/IGRT had a significant incidence of fecal incontinence, which negatively affected the quality of life of survivors.Trial registry: The study protocol was registered on clinicaltrials.gov (NCT04262609) on 5 February 2020.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4003-4010"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03926-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Fecal incontinence (FI) is a late toxicity consequence in prostate cancer patients treated with current radiotherapy schedules that remains poorly described and understood. The main objective of this work is to describe the incidence of appearance of FI in these patients, and to analyze whether this late radiotoxicity event affects the quality of life of survivors.

Methods: Prospective follow-up study was performed on a cohort of 91 patients with non-metastatic prostate cancer undergoing moderately hypofractionated volumetric modulated arc therapy (VMAT at 2.5-3 Gy/session) with image-guided radiotherapy (IGRT) in a real-world clinical practice scenario. The incidence of FI (using the Vaizey score) and FI-free survival time after completion of radiotherapy were presented. We additionally assessed the scores on the FI Quality of Life (FIQL) scale in both patients with and without FI.

Results: Within 2 years after radiotherapy, 10 of 91 patients (11%) showed some degree of FI with an average onset at 13.59 months. Patients with some degree of FI had worse FIQL scores than those without FI (p < 0.001).

Conclusion: Patients with localized prostate cancer treated with moderately hypofractionated VMAT/IGRT had a significant incidence of fecal incontinence, which negatively affected the quality of life of survivors.

Trial registry: The study protocol was registered on clinicaltrials.gov (NCT04262609) on 5 February 2020.

查看原文本刊更多论文

中度低分割体积调节弧线治疗前列腺癌后大便失禁：发病率和对生活质量的影响。

目的：大便失禁（FI）是目前放疗方案治疗前列腺癌患者的一种晚期毒性后果，其描述和理解仍然很少。这项工作的主要目的是描述FI在这些患者中出现的发生率，并分析这种晚期放射毒性事件是否影响幸存者的生活质量。方法：对91例非转移性前列腺癌患者进行前瞻性随访研究，这些患者在现实世界的临床实践场景中接受中度低分割体积调节电弧治疗（VMAT， 2.5-3 Gy/次）和图像引导放疗（IGRT）。报告放疗结束后FI发生率（采用Vaizey评分）和无FI生存时间。我们还评估了有和无FI患者的FI生活质量（FIQL）量表得分。结果：91例患者放疗后2年内有10例（11%）出现不同程度的FI，平均发病时间为13.59个月。有一定程度FI的患者FIQL评分较无FI的患者差(p)。结论：中度低分割VMAT/IGRT治疗的局限性前列腺癌患者存在显著的尿失禁发生率，这对幸存者的生活质量产生了负面影响。试验注册：该研究方案于2020年2月5日在clinicaltrials.gov （NCT04262609） 上注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.